India must not let US Section 301 threats push it into a lopsided trade deal: Experts

Trade experts have cautioned against India accepting an interim bilateral trade agreement with the United States that may be weighted heavily in Washington's...

What Happened

Trade experts have cautioned against India accepting an interim bilateral trade agreement with the United States that may be weighted heavily in Washington's favour, under pressure from threatened US Section 301 investigations.
The US and India announced a framework for an interim Bilateral Trade Agreement (BTA) in February 2026, reducing the US reciprocal tariff on Indian goods from 25% to 18%.
Washington has simultaneously initiated Section 301 investigations (March 2026) targeting structural excess manufacturing capacity in multiple countries, including India, citing a US$58 billion trade surplus India ran with the US in 2025.
India was also placed on the Priority Watch List in the 2026 USTR Special 301 Report on intellectual property (IP) protection and enforcement.
Experts warn that locking in at 18% tariffs does not guarantee immunity from future US protectionist measures — additional tariff threats (such as Section 301 actions) can be layered on separately regardless of the BTA.

Static Topic Bridges

Section 301 of the US Trade Act of 1974

Section 301 is a provision of the United States Trade Act of 1974 that grants the US Trade Representative (USTR) broad authority to investigate and respond to foreign government trade practices deemed "unreasonable," "discriminatory," or that "burden or restrict US commerce." Actions under Section 301 can lead to retaliatory tariffs, import restrictions, or other trade penalties.

There are two notable variants: - Section 301 (General): Targets unfair trade practices such as subsidies, non-tariff barriers, intellectual property violations. - Special 301: An annual review of trading partners' IP protection and enforcement practices; placement on the Priority Watch List can lead to investigations and sanctions.

In March 2026, the USTR initiated Section 301(b) investigations against 16 economies, including India, for structural excess capacity in manufacturing — a broader application that goes beyond IP disputes to address industrial policy.

Section 301 investigations can run parallel to and independent of bilateral trade agreements.
Retaliatory tariffs imposed under Section 301 are unilateral — they do not require WTO authorization.
India formally rejected US Section 301 excess capacity allegations in April 2026, demanding termination of the investigation.
India has been on USTR's Priority Watch List (Special 301) repeatedly over pharmaceutical patents, data protection, and copyright enforcement.

Connection to this news: The threat of Section 301 action on excess capacity — even as the bilateral tariff deal sets a baseline of 18% — shows that a negotiated tariff rate does not insulate India from additional protectionist measures. Experts argue this makes the 18% "lock-in" a weak shield against future US trade pressure.

India-US Bilateral Trade Architecture

The India-US trade relationship is the largest bilateral goods and services trade partnership for India. India ran a merchandise trade surplus of approximately US$58 billion with the US in 2025, making it one of Washington's largest deficit relationships. The interim BTA framework signed in February 2026 included:

US lowering the reciprocal tariff from 25% to 18% on Indian goods.
India committing to eliminate or reduce tariffs on all US goods, remove non-tariff barriers on medical devices, and accept US/international standards for various imports.
India pledging to purchase US$500 billion of US energy, aircraft, technology, precious metals, and coking coal over five years.
Continued negotiations on IP, customs, and remaining barriers.

The 18% tariff rate was set as the interim reciprocal tariff, replacing a 25% rate applied after Trump's reciprocal tariff executive order (April 2025).
India originally faced a 26% reciprocal tariff in the April 2025 executive order; the 90-day pause and negotiations brought it to 18%.
The BTA is an interim framework — full BTA negotiations continue, covering goods, services, IP, and investment.
India's key export sectors under pressure: pharmaceuticals, textiles, IT services, automobiles, gems and jewellery.

Connection to this news: Experts argue that signing a comprehensive BTA under duress from Section 301 threats means India is negotiating from a position of weakness, potentially making asymmetric concessions — such as opening sensitive sectors or accepting unfavourable IP norms — that disproportionately benefit US interests.

WTO Dispute Settlement and Unilateral Tariff Actions

Section 301 actions are unilateral US measures that have been repeatedly found incompatible with WTO obligations. The WTO Dispute Settlement Body ruled in 2019 that the US Section 301 tariffs on Chinese goods violated WTO rules (DS543). However, the WTO Appellate Body has been non-functional since December 2019 due to US blocking of new appointments — effectively neutering the enforcement mechanism.

WTO Appellate Body has been paralysed since December 2019; appeals are lodged but cannot be heard.
India and 26 other WTO members joined the Multi-Party Interim Appeal Arbitration Arrangement (MPIA) as an alternative appellate mechanism.
Without a functional WTO Appellate Body, unilateral Section 301 measures face no credible multilateral check.
India challenged several US tariff actions at WTO (e.g., steel/aluminium under DS518) with limited enforceability.

Connection to this news: The weakening of multilateral trade dispute mechanisms leaves countries like India with limited recourse when faced with US unilateral trade pressure. Bilateral deals negotiated under duress in this environment risk codifying asymmetric obligations.

India's Tariff Policy and Sensitive Sectors

India's average applied tariff rate (~12%) is significantly higher than the US (~3.3%) and most developed economies, reflecting its use of tariffs as an industrial policy instrument. Sectors India has historically protected include: agriculture, dairy, automobiles, electronics, and pharmaceuticals. Commitments under a BTA to "eliminate or reduce tariffs on all US goods" risk opening these sectors to competitive pressure before domestic industries are globally competitive.

India's simple mean applied MFN tariff: ~12% (WTO, 2024); US: ~3.3%.
Sensitive sectors for India in trade negotiations: dairy (US dairy lobby vs Indian cooperatives like Amul), poultry, agriculture, pharmaceuticals (data exclusivity vs compulsory licensing).
India's patent regime under the Patents Act, 1970 (as amended in 2005) — particularly Section 3(d) limiting evergreening — is a recurring friction point with the US pharma industry.
Data localisation requirements and e-commerce market access rules are additional non-tariff barriers the US seeks to address.

Connection to this news: Experts' core concern is that Section 301 threat creates negotiating pressure on India to make pre-emptive concessions on these sensitive sectors without securing equivalent market-access gains in services (where India has competitive advantage, e.g., IT, skilled professionals).

Key Facts & Data

India's trade surplus with US in 2025: ~US$58 billion
US reciprocal tariff on India: reduced from 25% to 18% under the February 2026 interim framework
Section 301 investigations on excess manufacturing capacity initiated: March 2026 (16 economies including India)
India placed on USTR Special 301 Priority Watch List: 2026 report
India formally rejected Section 301 excess-capacity allegations: April 2026
India's commitment under interim BTA: US$500 billion in US product purchases over 5 years
India's average applied MFN tariff: ~12% vs US ~3.3%
WTO Appellate Body non-functional since: December 2019
Key Indian exports at risk: pharmaceuticals, textiles, gems and jewellery, automobiles, IT services
India is the US's 8th largest trading partner (goods); US is India's largest goods export destination